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Clinical improvement of diabetes mellitus 
type 1 by b-D-mannuronic acid (M2000) in  
a breast cancer patient — as a case report
ABSTRACT
A 56 years old female with breast cancer (BC) and poor 
controlled diabetes mellitus type 1 (DM1) which has 
registered in a clinical trial for assessment of thera-
peutic efficacy of b-D-mannuronic acid (M2000) on 
pre-surgical BC patients is described in this case report. 
After receiving M2000, the patient was followed for 
9 weeks. During this period, cancer mass details, fast-
ing blood glucose (FBG) levels, 2-hour post-prandial 
blood glucose (2HPP), blood uric acid (BUA) level and 
urine analysis (UA) were continuously controlled. After 
9 weeks of treatment with M2000, her FBG, BUA and 
UA decreased significantly. This finding was exactly 
in accordance with our published experimental data 
about the anti-diabetic effect of M2000 in an animal 
model. Therefore, it might be concluded that M2000 is 
probably able to improve DM1 by reducing FBG level, 
BUA level, glycosuria, ketonuria and proteinuria. (Clin 
Diabetol 2019; 8, 4: 227–229)
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Introduction
BC patients with DM1 have poor prognosis with un-
known mechanism [1]. Non-steroidal anti-inflammatory 
drugs (NSAIDs) are among the drugs prescribed for 
BC and DM1 [1]. However, their excessive use can be 
associated with adverse effects in the gastrointestinal 
tract, which limits their use in certain cases [2]. 
Alginates are linear copolymers found in brown 
seaweed and consist of b-D-mannuronic acid (M-block) 
and a-L-guluronic acid (G-block) which are bound 
together by 1,4 glycoside bonds. M2000 (Patent PCT/ 
/EP2017/067919) is a low molecular weight small 
molecule (C6H10O7) which is produced from sodium 
alginate, based on the protocol of Mirshafiey, et al. 
The purity of the M2000 has been confirmed using 
Carbon-13 Nuclear Magnetic Resonance (13C-NMR) 
and Fourier Transform Infrared Spectroscopy (FT-IR) [3]. 
Some data showed M2000 is a NSAID with a prominent 
immunosuppressive feature which can be used safely 
[4]. The molecular mechanism of therapeutic efficacy 
of this novel drug is based on its inhibitory effects 
on matrix metalloproteinase 2, 9 (MMP2, 9) activity, 
decrease in immune cells infiltration in inflammatory 
foci, blocking the toll-like receptor 2, 4 (TLR2, 4) down-
stream signaling transduction pathway, reduction of 
the level of inflammatory cytokine such as interleukin 
(IL)-6 and tumor necrosis factor (TNF)-a, a decrease in 
antibody production and induction of apoptosis using 
fibrosarcoma cell line [5, 6]. In this study, another effect 
of M2000 in the treatment of DM1 was presented for 
the first time as a case report in an ongoing phase I 
and II clinical trials on Iranian BC patients. In this report, 
a 56-year-old patient diagnosed with BC and poor 
controlled DM1 is introduced. 
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Case report
A 56 years old female with the body mass index of 
30.1 kg/m2 (height: 164 cm, weight: 81 kg) patient with 
BC that refused surgery and chemotherapy selected. 
She accepted treatment with M2000 for BC. She also 
had uncontrolled DM1 diagnosed 8 years ago, receiv-
ing 68 units of Lantus and Novorapid insulin daily (24 
units in the morning, 22 units in the afternoon and 22 
units at night). Mean daily glycaemia was 206 ± 15 
mg/dL. Patient had no comorbid diseases nor diabetic 
complications. Treatment with M2000 was started at 
a dose of 1000 mg per day for 9 weeks to evaluate its ef-
fect on breast tumor growth. Laboratory data changes 
are shown in Table 1. The patient did not report side 
effects during the treatment. 
Discussion
The dysregulated metabolism in poorly controlled 
diabetes causes a long-term pro-inflammatory condi-
tion characterized by increased levels of IL-6, TNF-a, 
C-reactive protein (CRP) and other markers of chronic 
inflammation [2]. Recent evidence suggested that, 
persistent inflammation may contribute to genetic in-
stability and chronic forms of inflammation can increase 
the risk of cancer [1]. This finding is also confirmed 
by credible evidence regarding the reducing effect of 
NSAIDs on the risk of certain types of cancer [1, 6].
The mechanism of inflammation in diabetic pa-
tients is unclear. Chronic oxidative stress is associated 
with chronic inflammation. Oxidants affect almost all 
stages of the inflammatory response process, includ-
ing the release of inflammatory cytokines, sensing by 
innate immune receptors of TLRs, nucleotide-binding 
oligomerization domain-like receptors and activating the 
triggering signaling of the adaptive cellular response to 
such signals. Reactive oxygen species may damage lipids, 
proteins and DNA and then begin carcinogenesis [2]. In 
addition, chronic inflammation is associated with the in-
creased levels of TNF-a, which strongly activates nuclear 
factor kappa B (NF-kB) and enhances the downstream 
signaling transduction, ultimately leading to progression 
of many tumors [7]. NF-kB protein complex contributes 
to the proliferation and survival of malignant cells, 
increases angiogenesis, metastasis, damages adaptive 
immunity and mediates the response to hormones and 
chemotherapy drugs. Therefore, long-term exposure 
to chronic inflammation and oxidative stress results in 
conversion of susceptible cells to malignant cells [8].
The main objective of this study was to improve BC 
by reducing tumor growth using M2000. M2000 was 
introduced as a novel NSAID with immunosuppressive 
effects due to its impact on the expression and activity 
of cyclooxygenase 1, 2 (COX1, 2) genes. In terms of the 
molecular mechanism, this new drug exerts its thera-
peutic effect through inhibiting the activity of MMP2 
and MMP9, reducing the infiltration of immune cells in 
inflammatory foci, decreasing the level of inflammatory 
cytokines IL6 and IL17, reducing antibody production 
and inducing apoptosis using fibro sarcoma cell line. 
The results of a study showed that, this new NSAID can 
affect the M2000-treated mice through decreasing the 
expression levels of blood glucose, Scavenger receptor-
A (SR-A), Lipoxygenase-1 (LOX-1), CD36 and CD68 
compared to untreated diabetic rats (Figure 1) [9, 10]. 
Collectively, after 9 weeks of follow-up, there was 
a significant improvement in the level of FBG, 2HPP 
and UA in the patient with DM1. Therefore, it might 
be concluded that M2000 is a new NSAID that can 
improve DM1 in patients with BC. 
Table 1. Laboratory data changes during treatment with M2000
Parameter A day before  
treatment
3rd week after  
treatment
6th week after  
treatment
9th week after  
treatment
FBG [mg/dL] 189 122 101 91
2HPP [mg/dL] 260 246 223 196
Uric acid [mg/dL] 8.2 7.6 6.3 5.8
Proteinuria [mg/dl] 321 255 208 117
Glycosuria [mmol/l] 1.9 1.5 1.2 1
Ketonuria [mmol/l] 2.3 1.4 1 0.7
FBG — fasting blood glucose; 2HPP — 2 hour post-prandial
Figure 1. Schematic hypothesis: the anti-diabetic effect of 
M2000
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